Clinicians have long observed that co-infections worsen pediatric HIV outcomes. A new study links CMV viraemia mortality HIV risks when starting antiretroviral therapy (ART). While CMV impacts adult mortality, its specific role in children was previously unclear. This research clarifies the significant threat posed by Cytomegalovirus in younger populations.

The Impact of CMV Viraemia Mortality HIV Factors

Researchers analyzed 498 children in Uganda and Zimbabwe as part of the ARROW trial. They measured CMV levels at ART initiation and during follow-up. Detectable CMV viraemia at baseline strongly predicted death across different cohorts. In Zimbabwe, higher viral loads were associated with a two-fold increase in mortality risk. Similarly, Ugandan children with viraemia faced a three-fold higher death risk compared to those with undetectable levels.

Clinical Management and Future Directions

The study found no direct link between CMV and increased immune activation. This suggests that the biological pathways to death might differ from general inflammation. Consequently, healthcare providers should consider CMV screening during ART initiation in high-burden settings. Furthermore, clinical trials must evaluate if suppressing CMV viraemia can directly improve survival for these vulnerable children. Therefore, proactive monitoring could be a vital step in pediatric care.

FAQs

How common is CMV viraemia in children starting HIV treatment?

Prevalence varies by region and assay sensitivity. In this study, detectable CMV ranged from 26% in Uganda to 73% in Zimbabwe at the start of treatment.

Does CMV viraemia correlate with immune activation in children?

According to the findings, there was no evidence that CMV viraemia was associated with increased immune activation in the analyzed subset of pediatric patients.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Fisayo T et al. CMV viraemia is associated with mortality among children with HIV starting antiretroviral therapy in sub-Saharan Africa. Clin Infect Dis. 2026 Jun 09. doi: undefined. PMID: 42262841.

Velaphi S et al. Investigating the role of cytomegalovirus as a cause of stillbirths and child deaths in low and middle-income countries through postmortem minimally invasive tissue sampling. Clin Infect Dis. 2025. doi: 10.1093/cid/ciaf098.

Skipper CP et al. Cytomegalovirus viremia increases mortality risk in HIV-associated meningitis. EATG. 2022. Available at: https://www.eatg.org/news/cytomegalovirus-viremia-increases-mortality-risk-in-hiv-associated-meningitis/.